Skip to main content

Table 1 (abstract O2) Efficacy in KEYNOTE-045

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

End point Pembrolizumab
N = 270
Chemotherapy
N = 272
OS, no. of events 155 179
 Median (95 % CI), months 10.3 (8.0-11.8) 7.4 (6.1-8.3)
 HR (95 % CI) 0.73 (0.59-0.91); P = 0.0022
PFS, no. of events 218 219
 Median (95 % CI), months 2.1 (2.0-2.2) 3.3 (2.3-3.5)
 HR (95 % CI) 0.98 (0.81-1.19); P = 0.42
ORR (95 % CI) 21.1 % (16.4-26.5) 11.4 % (7.9-15.8)
 Treatment difference, % (95 % CI) 9.6 (3.5-15.9); P = 0.0011